MedTrace Logo

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

NCT04431791 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 268

Last updated 2020-06-16

No results posted yet for this study

Summary

This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China. About 268 eligible metastatic colorectal cancer patients after second-line therapy will be assigned to receive either regorafenib or fruquintinib, based on decision of the gastrointestinal physician according the patients' condition.

Conditions

Interventions

DRUG

Regorafenib

oral regorafenib

DRUG

Fruquintinib

oral fruquintinib

Sponsors & Collaborators

  • Peking University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-25
Primary Completion
2021-08-01
Completion
2022-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04431791 on ClinicalTrials.gov